Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACUVUE THERAVISION WITH KETOTIFEN vs ACUVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
Reduction of ocular pain and inflammation following cataract surgery,Treatment of ocular itching associated with seasonal allergic conjunctivitis
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1 drop in the affected eye 4 times daily.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Primarily hepatic via conjugation with glucuronic acid; minor role of cytochrome P450 enzymes. Approximately 50% is excreted as parent drug and metabolites in urine.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
99% (primarily albumin and alpha-1-acid glycoprotein).
>99% bound to plasma proteins, primarily albumin.
2.4 L/kg (high tissue distribution, including ocular tissues).
Intravenous administration in animals suggests Vd ~0.15 L/kg, indicating limited distribution; clinically, it distributes into aqueous humor after topical dosing.
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
Ocular bioavailability is dependent on formulation; systemic bioavailability after topical ocular administration is extremely low (<1%).
No dosage adjustment required based on renal function; systemic absorption is minimal.
No adjustment required. Drug is minimally systemically absorbed.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
No adjustment required. Drug is minimally systemically absorbed.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Safety and efficacy in pediatric patients have not been established.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
No specific dosage adjustment is recommended; use same dose as younger adults.
None
No black box warning for ophthalmic use; however, systemic NSAIDs carry risk of serious cardiovascular and gastrointestinal events. Ophthalmic use rarely associated with corneal adverse events.
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Use with caution in patients with bleeding disorders or those on anticoagulants; may prolong bleeding time. Avoid in patients with known hypersensitivities to NSAIDs or aspirin. Can cause corneal keratopathy; discontinue if corneal epithelial breakdown occurs.
Hypersensitivity to ketotifen or any component of the product.
Hypersensitivity to any component of the formulation. Active corneal epithelial defect. Patients with aspirin-sensitive asthma.
None reported.
No specific food interactions; systemic absorption is minimal with ophthalmic use. Avoid concurrent use of other NSAID eye drops due to additive irritation.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause premature closure of the ductus arteriosus and oligohydramnios in the third trimester. Use during the first and second trimesters should be limited to cases where potential benefit outweighs risk; avoid during the third trimester due to risk of fetal harm.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
Ketorolac is excreted in human milk following systemic administration, but ocular doses produce negligible systemic levels. The M/P ratio is not determined for ophthalmic use. Use with caution in nursing mothers, as the clinical significance is likely low due to minimal systemic absorption.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
No dosage adjustment is required for ophthalmic use during pregnancy, as systemic exposure is negligible. However, avoid use in third trimester due to risks. Pharmacokinetic changes in pregnancy do not significantly alter ocular delivery.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonsteroidal anti-inflammatory drug (NSAID) for ocular use. It is preserved with sodium chloride and not benzalkonium chloride, reducing corneal epithelial toxicity. Administer 1 drop twice daily for ocular pain and inflammation following cataract surgery. Use caution in patients with bleeding tendencies or those on anticoagulants due to risk of increased ocular bleeding. Monitor for corneal epithelial defects and keratitis, especially with prolonged use.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
Wash hands before each use; do not touch tip of bottle to eye or any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Contact your doctor if you experience eye pain, redness, vision changes, or if symptoms worsen.,Do not use this medication while wearing contact lenses unless directed by your doctor.,Store at room temperature, keep bottle tightly closed when not in use, and discard within 28 days of opening.
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACUVUE THERAVISION WITH KETOTIFEN vs ACUVAIL, answered by our medical review team.
ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. ACUVAIL is a NSAID Ophthalmic that works by Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACUVUE THERAVISION WITH KETOTIFEN and ACUVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. The standard adult dose of ACUVAIL is: 1 drop in the affected eye 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACUVUE THERAVISION WITH KETOTIFEN and ACUVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. ACUVAIL is classified as Category C. Acuvail (ketorolac tromethamine ophthalmic solution) is classified as FDA Pregnancy Category C. Systemic exposure after ocular administration is minimal; however, NSAIDs may cause . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.